Holen Sie sich die Stockscreener-App
5.88
0.51%
-0.03
Handel nachbörslich:
5.98
0.10
+1.70%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$5.91
Offen:
$5.99
24-Stunden-Volumen:
11.42M
Relative Volume:
1.58
Marktkapitalisierung:
$1.79B
Einnahmen:
$32.77M
Nettoeinkommen (Verlust:
$-440.22M
KGV:
-3.521
EPS:
-1.67
Netto-Cashflow:
$-400.48M
1W Leistung:
-0.17%
1M Leistung:
-20.33%
6M Leistung:
-26.13%
1J Leistung:
-24.42%
1-Tages-Spanne:
$5.57
$6.06
1-Wochen-Bereich:
$5.57
$6.28
52-Wochen-Spanne:
$5.57
$18.33
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Firmenname
Iovance Biotherapeutics Inc
Sektor
Branche
Telefon
(650) 260-7120
Adresse
825 INDUSTRIAL ROAD, SAN CARLOS
Vergleichen Sie IOVA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
5.88 | 1.79B | 32.77M | -440.22M | -400.48M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-07-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Eingeleitet | Goldman | Buy |
| 2023-09-18 | Bestätigt | Barclays | Overweight |
| 2023-05-30 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2023-01-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-31 | Eingeleitet | Guggenheim | Neutral |
| 2022-08-18 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-01-28 | Hochstufung | Stifel | Hold → Buy |
| 2021-12-07 | Fortgesetzt | Cowen | Outperform |
| 2021-06-10 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Herabstufung | Stifel | Buy → Hold |
| 2021-05-03 | Eingeleitet | Truist | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Eingeleitet | Mizuho | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2019-10-01 | Eingeleitet | Stifel | Buy |
| 2019-04-29 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-02-28 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-02-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-12-31 | Fortgesetzt | B. Riley FBR | Buy |
| 2018-07-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-04-10 | Hochstufung | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Bestätigt | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-11-01 | Bestätigt | B. Riley FBR, Inc. | Buy |
Alle ansehen
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
(IOVA) Technical Pivots with Risk Controls - Stock Traders Daily
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 52-Week LowHere's Why - MarketBeat
Cervical Cancer Market Expected to Experience Major Growth - openPR
Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks - Insider Monkey
Is Iovance Biotherapeutics (IOVA) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Yahoo Finance
1,746,877 Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Purchased by Assenagon Asset Management S.A. - MarketBeat
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Iovance Biotherapeutics Awards 224,550 Stock Options to Expand Team with 41 New Hires - StockTitan
First Week of September 19th Options Trading For Iovance Biotherapeutics (IOVA) - Nasdaq
Iovance Biotherapeutics (NASDAQ:IOVA) Sets New 1-Year LowTime to Sell? - MarketBeat
Oversold Conditions For Iovance Biotherapeutics (IOVA) - Nasdaq
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) May Have Run Too Fast Too Soon With Recent 25% Price Plummet - Simply Wall St
How To Trade (IOVA) - Stock Traders Daily
Cancer Drug Maker Iovance Tumbles Toward Worst Week Since November, But Retail Feels Macro Selloff Overblown - MSN
Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price Down 7.8%Here's Why - MarketBeat
Iovance Biotherapeutics Shares Are Falling Today: What's Going On? - Benzinga
Immunotoxins Market Trends and Regional Business Opportunities, 2024-2034: Diphtheria Toxin-Based Immunotoxins Lead Revenue, Pseudomonas Exotoxins Show Rapid Growth Potential - GlobeNewswire Inc.
Iovance Biotherapeutics (IOVA) Surges on Positive Analyst Outloo - GuruFocus.com
Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today - MSN
Stifel maintains Buy on Iovance Biotherapeutics stock, optimistic on Amtagvi By Investing.com - Investing.com Canada
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Up 7.7%What's Next? - MarketBeat
Why Iovance Biotherapeutics Inc. (IOVA) Is Skyrocketing - MSN
Analysts Set Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Price Target at $23.00 - MarketBeat
Philly’s year in biopharma: a look back at 2024 - The Philadelphia Inquirer
The Immunotherapy Boom: What It Means for the Future of Cancer Treatment - Baystreet.ca
Principal Financial Group Inc. Has $37.87 Million Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Geode Capital Management LLC Cuts Position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Purchased by Barclays PLC - MarketBeat
Where are the Opportunities in (IOVA) - Stock Traders Daily
Insiders' US$48.3m Investments In Red Following Iovance Biotherapeutics' US$402m Dip In Market Value - Simply Wall St
Iovance Biotherapeutics is Now Oversold (IOVA) - Nasdaq
KEI Comments on NIH Exclusive License to Iovance for T-cell Vaccine for Cancer Treatment - Knowledge Ecology International
Iovance Biotherapeutics: Amtagvi Launch Growing, But Stock Isn't (NASDAQ:IOVA) - Seeking Alpha
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Sees Significant Increase in Short Interest - MarketBeat
State Street Corp Grows Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Iovance Biotherapeutics' SWOT analysis: promising TIL therapy stock faces growth hurdles - Investing.com India
Interesting IOVA Call Options For January 2025 - Nasdaq
Prediction: This Stock Will Beat the Market in 2025 - Yahoo Finance
BNP Paribas Financial Markets Trims Stock Holdings in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - MarketBeat
Iovance Biotherapeutics' SWOT analysis: stock shows promise amid challenges By Investing.com - Investing.com Nigeria
Iovance Biotherapeutics: Steady Progress (NASDAQ:IOVA) - Seeking Alpha
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Finanzdaten der Iovance Biotherapeutics Inc-Aktie (IOVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):